Skip to content
DraconiticResearch
Search Sources API
197,787 studies31 sourcesUpdated just now
Peer-reviewedCC BY-NC-NDBlood neoplasia

Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis

  • Andrew P. Jallouk1
  • Lorenzo Falchi2
  • Ayushi Chauhan3
  • Geoffrey Shouse4
  • Swetha K. Thiruvengadam4
  • Yazeed Sawalha5
  • Sonia Godbole5
  • Ajay Major6
  • Reid W. Merryman7
  • Shakthi T. Bhaskar1
  • Allison M. Bock8
  • Mehdi Hamadani9
10 more authors
  • Amy Ayers3
  • Omnia Farahat3
  • Narendranath Epperla8
  • Jennifer L. Crombie7
  • Steven Bair6
  • Mathew A. Lunning10
  • Alex F. Herrera4
  • Christopher R. Flowers3
  • Gilles Salles2
  • Sairah Ahmed3
10 affiliations
  1. 1Vanderbilt University Medical Center, Nashville, TN
  2. 2Memorial Sloan Kettering Cancer Center, New York, NY
  3. 3University of Texas MD Anderson Cancer Center, Houston, TX
  4. 4City of Hope National Medical Center, Duarte, CA
  5. 5The Ohio State University James Comprehensive Cancer Center, Columbus, OH
  6. 6Division of Hematology, University of Colorado School of Medicine, Aurora, CO
  7. 7Dana-Farber Cancer Institute, Boston, MA
  8. 8Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
  9. 9BMT and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
  10. 10Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE
Read full textPDFCite

Related

  1. Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
    Aimaz Afrough, Oren Pasvolsky, Andrew J. Portuguese +52
    Blood cancer journalPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJ
  2. Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
    Holger N. Lode, Przemysław Holko, Aleksandra Wieczorek +17
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
    Matilda Arvidsson Kvissberg, Christer Nilsson, Niklas Landberg +6
    Annals of hematologyPeer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ
  4. BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort
    Titouan Cazaubiel, Olivier Decaux, Aurore Perrot +21
    European Journal of HaematologyPeer-reviewedCC BY 4.0Full textGeneral biologyOncologyHAL
  5. Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL
    Stephan A. Grupp, Shannon L. Maude, Susana Rives +26
    Journal of Clinical OncologyPeer-reviewedCC BY-NC-ND 4.0Full text1 citedOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{jallouk2026realworld,
  title = {{Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis}},
  author = {Andrew P. Jallouk and Lorenzo Falchi and Ayushi Chauhan and Geoffrey Shouse and Swetha K. Thiruvengadam and Yazeed Sawalha and Sonia Godbole and Ajay Major and Reid W. Merryman and Shakthi T. Bhaskar and Allison M. Bock and Mehdi Hamadani and Amy Ayers and Omnia Farahat and Narendranath Epperla and Jennifer L. Crombie and Steven Bair and Mathew A. Lunning and Alex F. Herrera and Christopher R. Flowers and Gilles Salles and Sairah Ahmed},
  journal = {Blood neoplasia},
  year = {2026},
  month = jul,
  url = {https://europepmc.org/article/PMC/PMC13676093},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis
AU  - Andrew P. Jallouk
AU  - Lorenzo Falchi
AU  - Ayushi Chauhan
AU  - Geoffrey Shouse
AU  - Swetha K. Thiruvengadam
AU  - Yazeed Sawalha
AU  - Sonia Godbole
AU  - Ajay Major
AU  - Reid W. Merryman
AU  - Shakthi T. Bhaskar
AU  - Allison M. Bock
AU  - Mehdi Hamadani
AU  - Amy Ayers
AU  - Omnia Farahat
AU  - Narendranath Epperla
AU  - Jennifer L. Crombie
AU  - Steven Bair
AU  - Mathew A. Lunning
AU  - Alex F. Herrera
AU  - Christopher R. Flowers
AU  - Gilles Salles
AU  - Sairah Ahmed
PY  - 2026
DA  - 2026/07/28
JO  - Blood neoplasia
UR  - https://europepmc.org/article/PMC/PMC13676093
SN  - 2950-3280
ER  -